A Study of the Efficacy and Safety of 24 Week Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study
designed to investigate the efficacy and safety of REN001 administered once daily over a
24-week period to patients with PMM.